Targeted Immune Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates

Time: 1:30 pm
day: Day One


  • Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform delivers potent TLR-9 (T-CpG) for targeted immune activation via systemic administration
  • TRAAC platform is amenable for immune-targeting, tumor/immune-targeting and tumor-targeting to promote adaptive and innate responses
  • TAC-001, CD22 TRAAAC, targets B-cells to drive potent anti-tumor activity in preclinical solid tumor models